Brief: Harpoon Therapeutics Says Presents Updated Interim Results At ASH 2022 For Novel T Cell Engager Hpn217 In Relapsed/Refractory Multiple Myeloma
11/12/2022 15:09
Dec 11 (Reuters) - Harpoon Therapeutics Inc HARP.O :
* HARPOON THERAPEUTICS PRESENTS UPDATED INTERIM RESULTS AT
ASH
2022 FOR NOVEL T CELL ENGAGER HPN217 IN RELAPSED/REFRACTORY
MULTIPLE MYELOMA
* 77% (10/13) OBJECTIVE RESPONSE RATE (ORR) OBSERVED ACROSS
HIGHEST DOSES (12 AND 24 MG)
* RESPONSES WERE DURABLE, WITH MANY PATIENTS ON TREATMENT
LONGER
THAN A YEAR
Source text for Eikon: ID:nGNX3BltTy
Further company coverage: HARP.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Harpoon Therapeutics
See all newsBrief: Harpoon Therapeutics Receives 17 Additional Demands Seeking Disclosures in Proxy Statement
U.S. RESEARCH ROUNDUP-Axonics, BlackRock, Credit Acceptance
U.S. STOCKS ON THE MOVE-Core & Main, Commercial Metals, Equifax
U.S. STOCKS ON THE MOVE-Toll Brothers, American Eagle Outfitters, Twilio
Wrapup 1: Drugmakers kick off industry conference with two cancer deals